UTAH MEDICAL PRODUCTS INC UTMD
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
47.39
Altman Z″ — distress risk · safe
—
Dividend payout · n/a
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $38.5M | — | $22.0M | $14.3M | $119.3M |
| 2024 | $40.9M | — | $24.1M | $14.6M | $117.4M |
| 2023 | $50.2M | — | $30.0M | $21.6M | $128.3M |
| 2022 | $52.3M | — | $32.2M | $20.3M | $114.3M |
| 2021 | $49.1M | — | $30.9M | $20.7M | $107.1M |
| 2020 | $42.2M | — | $25.5M | $19.3M | $102.8M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 47.39 (safe)
- Working capital / assets 0.776
- Retained earnings / assets 1.05
- EBIT / assets 0.093
- Equity / liabilities 36.429
Source: SEC EDGAR filings · CIK 0000706698 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.